Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Metagenomi Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 4 examiners and 3 art units, indicating a broader prosecution footprint than a single-examiner portfolio.
HOLLAND, PAUL J is the busiest examiner, handling 2 pending matters. The remaining matters are spread across other examination assignments, so counsel may need coordinated but examiner-specific response planning.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 2 | 57.3% | +64.7% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18180633 | BASE EDITING ENZYMES | MOAZZAMI, NAGHMEH NINA | 9d |
| 18816810 | CLASS II, TYPE V CRISPR SYSTEMS | HOLLAND, PAUL J | — |
| 18840723 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | HOLLAND, PAUL J | — |
| 18481769 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | SULLIVAN, STEPHANIE LAUREN | — |
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1656 | 2 |
| 1635 | 2 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18816810 | CLASS II, TYPE V CRISPR SYSTEMS | HOLLAND, PAUL J | 1656 | Other | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18840723 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | HOLLAND, PAUL J | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18481769 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | SULLIVAN, STEPHANIE LAUREN | 1635 | §112Other | Final Rejection | — | Pending | Oct 05, 2023 |
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2023 |
| 18180633 | BASE EDITING ENZYMES | MOAZZAMI, NAGHMEH NINA | 1652 | §112Other | Final Rejection | 9d | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetagenomi Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Paul J Holland has the most, with 2 of Metagenomi Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
